Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.41 USD
Change Today +0.04 / 0.30%
Volume 82.5K
STML On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

stemline therapeutics inc (STML) Snapshot

Open
$13.50
Previous Close
$13.37
Day High
$13.82
Day Low
$13.23
52 Week High
01/6/15 - $18.94
52 Week Low
09/5/14 - $10.50
Market Cap
240.1M
Average Volume 10 Days
111.3K
EPS TTM
$-2.23
Shares Outstanding
17.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEMLINE THERAPEUTICS INC (STML)

Related News

No related news articles were found.

stemline therapeutics inc (STML) Related Businessweek News

No Related Businessweek News Found

stemline therapeutics inc (STML) Details

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors in the United States. It develops SL-401, a clinically active targeted therapy directed to the interleukin-3 receptor, which has completed Phase I/II clinical trials for advanced hematologic cancers; and SL-701, an immunotherapy to attack tumors that has completed Phase I/II clinical trials. The company’s preclinical candidates include SL-801, a novel oral small molecule reversible inhibitor of nuclear transport for the treatment of solid and hematologic cancers; and SL-501, a next-generation IL-3R-targeted therapy for the treatment of various autoimmune diseases. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

22 Employees
Last Reported Date: 03/16/15
Founded in 2003

stemline therapeutics inc (STML) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $875.0K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: $359.8K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $600.0K
Chief Medical Officer, Head of Research & Dev...
Total Annual Compensation: $600.0K
Compensation as of Fiscal Year 2014.

stemline therapeutics inc (STML) Key Developments

Stemline Therapeutics, Inc. Appoints Alan S. Forman as Director

On April 27, 2015, the Board of Directors of Stemline Therapeutics, Inc. appointed Alan S. Forman to the Board. Mr. Forman will serve as a director until his term expires at the 2015 annual meeting of stockholders, at which time he will stand for election by the company's stockholders. Alan S. Forman is a Director of Investments at the Yale University Investments Office.

Stemline Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Stemline Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported grant revenue of $121,429 compared to $71,000 a year ago. Loss from operations was $6,962,477 compared to $7,917,009 a year ago. Net loss attributable to common stockholders was $6,932,194 or $0.53 per basic and diluted share compared to $7,666,703 or $0.60 per basic and diluted share a year ago. Net loss from operations was $6,932,194 against $7,666,703 a year ago. For the year, the company reported grant revenue of $335,287 compared to $71,000 a year ago. Loss from operations was $28,989,892 compared to $23,979,463 a year ago. Net loss attributable to common stockholders was $28,829,975 or $2.23 per basic and diluted share compared to $24,196,511 or $2.35 per basic and diluted share a year ago. Net loss from operations was $28,829,975 against $24,196,511 a year ago.

Stemline Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 09:20 AM

Stemline Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 09:20 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Ivan Bergstein, Founder, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STML:US $13.41 USD +0.04

STML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for STML.
View Industry Companies
 

Industry Analysis

STML

Industry Average

Valuation STML Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMLINE THERAPEUTICS INC, please visit www.stemline.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.